Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

Evaluation of combined palliative radiation and ADXS31-164 in dogs with appendicular osteosarcoma (OSA)

May 20, 2014

Please Note: This study is now closed

As of 2-10-2015, additional secured funding will allow us to enroll 5 more dogs onto this clinical trial. Please contact us if you think your dog might qualify for the study.

Purpose of study: The purpose of this pilot study is to evaluate whether vaccination with a new tumor-targeting cancer vaccine (ADXS31-164) combined with radiation therapy can decrease bone cancer pain and prolong overall survival in dogs with OSA.

Eligibility criteria:

  • Dogs with suspected early OSA based on breed, clinical signs and radiographs
  • Dogs that are otherwise systemically healthy (no cancer spread to the lungs, no other health problems such as kidney disease, liver disease, heart disease etc.)
  • Dogs that are not candidates for amputation (either because they are too big or owners do not wish to pursue amputation)
  • Dogs that have not received prior treatment for OSA (other than pain medications)

Procedures covered by the study:
  • Physical examinations at each study visit (all visits take place at the University of Pennsylvania School of Veterinary Medicine).
  • Bone biopsy.
  • Two (2) doses of radiation therapy under general anesthesia.
  • Blood tests and immune evaluation at enrollment and at each vaccination.
  • Three complete staging evaluations including blood tests, urinalysis, limb radiographs, chest radiographs, ECG, and echocardiography.
  • Eight doses of Listeria monocytogenes huHer-2/neu recombinant vaccine.
  • Three days of antibiotics following each vaccine administration.
  • The treatment of any toxicity directly resulting from vaccine administration.

Dr. Nicola Mason
Phone:
215-898-3996
Email:
njmason@upenn.edu